Broadcast Date: January 12th, 2017
Time: 11:00 am ET, 8:00 am PT
In this webinar, you will learn how the Finnish Institute of Molecular Medicine (FIMM) and AstraZeneca have leveraged the unique capabilities of IntelliCyt’s iQue Screener platform to generate high-content data at high-speeds on heterogeneous cell populations using miniaturized cellular assays, or in a multiplexed, ultra-miniaturized, bead-based assay format. The iQue Screener enables more physiologically relevant assays to be performed faster, while conserving precious samples, saving costs and overcoming the limitations of traditional approaches thus paving the way for faster development of therapies and personalized medicines.
Who Should Attend
- Drug discovery scientists
- Cancer researchers
- Investigators interested in multiplexed cell-based and bead-based assays
- Scientists interested in precision medicine
- Researchers performing phenotypic screening
You Will Learn
- How FIMM develops precision medicine strategies for blood cancer patients through multiparametric drug sensitivity and resistance tests used to identify drugs and drug combinations that can effectively target tumor cells and monitor drug effects on immune cell response.
- How AstraZeneca ran a 500k compound cell viability screen and a target specific bead-based assay involving three of the major risk genes/factors associated with Amyotrophic Lateral Sclerosis (ALS) to identify novel inhibitors of target-induced toxicity.
Caroline Heckman, Ph.D.
Group Leader and Principal Investigator,
Institute for Molecular Medicine Finland (FIMM)
Catherine Bardelle, Ph.D.